Peritoneal carcinoma metastatic

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
2 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Anthracycline 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Phase II: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase II

1 trial
  • Bristol Myers Squibb International Corporation Commercial
    DOXORUBICIN HYDROCHLORIDE; FARLETUZUMAB ECTERIBULIN
    2023-504111-33-00 3 countries 2023 n=55
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Bristol Myers Squibb International Corporation Commercial 1 Phase II 0
New trials by year
2023
1
← All indication landscapes